{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:30:34Z","timestamp":1761183034353,"version":"build-2065373602"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.jiac.2021.07.018","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T17:18:54Z","timestamp":1627751934000},"page":"1750-1755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Successful treatment by glecaprevir\/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature"],"prefix":"10.1016","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6958-1366","authenticated-orcid":false,"given":"Tomoo","family":"Yamazaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Joshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Ichijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-ichi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5427-7628","authenticated-orcid":false,"given":"Ayumi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9883-8092","authenticated-orcid":false,"given":"Fumihiro","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2021.07.018_bib1","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.1840120409","article-title":"Interrelationship of blood transfusion, non-a, non-b hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis c virus","volume":"12","author":"Kiyosawa","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.jiac.2021.07.018_bib2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.jhep.2012.07.031","article-title":"Acute exacerbation and reactivation of chronic hepatitis c virus infection in cancer patients","volume":"57","author":"Mahale","year":"2012","journal-title":"J Hepatol"},{"issue":"Suppl S1","key":"10.1016\/j.jiac.2021.07.018_bib3","first-page":"1","article-title":"Jsh guidelines for the management of hepatitis b virus infection","volume":"44","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jiac.2021.07.018_bib4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jiac.2021.07.018_bib5","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.clml.2018.10.002","article-title":"Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment","volume":"19","author":"Frerichs","year":"2019","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.jiac.2021.07.018_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3960\/jslrt.19034","article-title":"Hepatitis b virus reactivation in a myeloma patient with resolved infection who received daratumumab-containing salvage chemotherapy","volume":"60","author":"Kikuchi","year":"2020","journal-title":"J Clin Exp Hematop"},{"key":"10.1016\/j.jiac.2021.07.018_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.29344","article-title":"Hepatitis c virus reactivation in patients receiving cancer treatment: a prospective observational study","volume":"67","author":"Torres","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jiac.2021.07.018_bib8","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0168-8278(96)80136-X","article-title":"Acute exacerbations in chronic hepatitis c: a clinicopathological and prognostic study","volume":"24","author":"Sheen","year":"1996","journal-title":"J Hepatol"},{"key":"10.1016\/j.jiac.2021.07.018_bib9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1086\/605561","article-title":"Improving the diagnosis of acute hepatitis c virus infection with expanded viral load criteria","volume":"49","author":"McGovern","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2021.07.018_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.29","article-title":"A randomized controlled trial of glycyrrhizin plus tenofovir vs. Tenofovir in chronic hepatitis b with severe acute exacerbation","volume":"8","author":"Hung","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jiac.2021.07.018_bib11","first-page":"192","article-title":"Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: a systematic review","volume":"4","author":"Reardon","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.jiac.2021.07.018_bib12","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/jvh.13302","article-title":"Severe acute exacerbation of hcv infection in cancer patients who undergo chemotherapy without antiviral prophylaxis","volume":"27","author":"Li","year":"2020","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jiac.2021.07.018_bib13","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2214\/ajr.176.4.1760891","article-title":"Periportal contrast enhancement and abnormal signal intensity on state-of-the-art mr images","volume":"176","author":"Ly","year":"2001","journal-title":"Am J Roentgenol"},{"key":"10.1016\/j.jiac.2021.07.018_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3904\/kjim.2005.20.1.80","article-title":"Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma","volume":"20","author":"Bae","year":"2005","journal-title":"Korean J Intern Med (Engl Ed)"},{"key":"10.1016\/j.jiac.2021.07.018_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.clon.2003.11.015","article-title":"Reactivation of hepatitis c virus after chemotherapy for colon cancer","volume":"16","author":"Melisko","year":"2004","journal-title":"Clin Oncol"},{"key":"10.1016\/j.jiac.2021.07.018_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.clml.2011.04.005","article-title":"Hepatitis c reactivation in patients who have diffuse large b-cell lymphoma treated with rituximab: a case report and review of literature","volume":"11","author":"Nooka","year":"2011","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.jiac.2021.07.018_bib17","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.2169\/internalmedicine.53.3194","article-title":"Hepatitis c virus (hcv) reactivation caused by steroid therapy for dermatomyositis","volume":"53","author":"Mori","year":"2014","journal-title":"Intern Med"},{"key":"10.1016\/j.jiac.2021.07.018_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv211","article-title":"Management of multiple myeloma complicated by hepatitis c virus reactivation: the role of new antiviral therapy","volume":"3","author":"Mahale","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jiac.2021.07.018_bib19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.msard.2016.08.003","article-title":"Hepatitis c virus (hcv) reactivation during fingolimod treatment for relapsing and remitting multiple sclerosis","volume":"9","author":"Tagawa","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jiac.2021.07.018_bib20","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jiac.2016.12.008","article-title":"Hepatitis c virus reactivation due to antiemetic steroid therapy during treatment of hepatocellular carcinoma","volume":"23","author":"Kawano","year":"2017","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2021.07.018_bib21","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis b virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jiac.2021.07.018_bib22","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2018.11.011","article-title":"Real-world effectiveness and safety of glecaprevir\/pibrentasvir in 723 patients with chronic hepatitis c","volume":"70","author":"D'Ambrosio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jiac.2021.07.018_bib23","first-page":"8","article-title":"Effectiveness of glecaprevir\/pibrentasvir for hepatitis c: real-world experience and clinical features of retreatment cases","author":"Sugiura","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.jiac.2021.07.018_bib24","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.bbmt.2015.07.033","article-title":"Hepatitis c virus infection among hematopoietic cell transplant donors and recipients: American society for blood and marrow transplantation task force recommendations","volume":"21","author":"Torres","year":"2015","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21002063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X21002063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:02:52Z","timestamp":1761159772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X21002063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1341321X21002063"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2021.07.018","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful treatment by glecaprevir\/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2021.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}